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Introduction
Human platelets circulate for around 10 days before they are
cleared.1 Although the trigger for platelet clearance has not
been fully resolved, intrinsic apoptosis delimits platelet
lifespan.2 Platelets lacking proapoptotic Bak/Bax have a
prolonged circulating half-life in vivo, whereas platelets
lacking prosurvival Bcl-xL have a very short circulating
half-life.3 Understanding platelet apoptosis is an important
step in understanding disorders of platelet number and
function, particularly for understanding the consequences
of drugs that trigger platelet apoptosis.
Prosurvival Bcl-2 family proteins, including Bcl-xL, are
upregulated in many cancers and have become attractive
targets for anticancer therapy.4,5 Prosurvival Bcl proteins can
be inhibited by BH3 mimetics. One BH3 mimetic, ABT-263
(navitoclax),which inhibits Bcl-2 andBcl-xL, is associatedwith
thrombocytopenia through activation of intrinsic apoptosis in
platelets.6,7This has been avoided through thedevelopment of







Abstract Platelet lifespan is limited by activation of intrinsic apoptosis. Apoptotic platelets are
rapidly cleared from the circulation in vivo. ABT-737 triggers platelet apoptosis and is a
useful tool for studying this process. However, in vitro experiments lack clearance
mechanisms for apoptotic platelets. To determine whether apoptotic platelets prog-
ress to secondary necrosis, apoptosis was triggered in human platelets with ABT-737, a
BH3 mimetic. Platelet annexin V (AnV) binding, release of AnVþ extracellular vesicles
(EVs), and loss of plasma membrane integrity were monitored by flow cytometry. ABT-
737 triggered AnV binding, indicating phosphatidylserine exposure, release of AnVþ
EVs, and a slow loss of plasma membrane integrity. The latter suggests that apoptotic
platelets progress to secondary necrosis in vitro. These responses were dependent on
caspase activation and Ca2þ entry. Surprisingly, although intracellular Ca2þ concentra-
tion increased, AnVþ EV release was not dependent on the Ca2þ-dependent protease,
calpain. On the contrary, ABT-737 downregulated the ability of the Ca2þ ionophore,
A23187, to trigger calpain-dependent release of AnVþ EVs. This was dependent on
caspase activity as, when caspases were inhibited, ABT-737 increased the ability of
A23187 to trigger AnVþ EV release. These data suggest that apoptotic platelets
progress to secondary necrosis unless they are cleared. This may affect the interpreta-
tion of ABT-737-triggered signaling in platelets in vitro. Ca2þ-dependent AnVþ EV
release is downregulated during apoptosis in a caspase-dependent manner, which may
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has been approved for treatment of chronic lymphocytic
leukemia.8–10
BH3 mimetics, such as ABT-737 (an analog of ABT-263),
have also become useful tools for investigating apoptosis in
platelets in vitro, leading to increased understanding of the
signaling that takes place.6,7,11–15 ABT-737 induces phos-
phatidylserine (PS) exposure in platelets in a relatively slow
manner—much slower than seen with Ca2þ ionophores or
procoagulant combinations of agonists (e.g., thrombin plus
collagen-related peptides).7,16 The greatest extent of PS
exposure is seen after 1 to 3 hours’ treatment and so signal-
ing studies often also investigate these late time points (e.g.,
see Refs. 6, 7, 15, and 17). However, it seems likely that an
apoptotic platelet would be cleared within this time under
normal circumstances.
Clearance of apoptotic cells in the body is usually rapid. If
apoptotic cells are not cleared rapidly they undergo secondary
necrosis, which may have proinflammatory or immunogenic
consequences.18 In vitro, in contrast, the scavengers of apo-
ptotic cells are not present and hence the apoptotic cells will
not be rapidly cleared. In this study, we investigated the effect
ofABT-737onplatelets invitro.Wedemonstrate that although
ABT-737 triggers apoptosis in platelets, this progresses
to secondary necrosis in vitro. This has important implications
for our understanding of platelet apoptosis. Furthermore, our
data show that during apoptosis, calpain-dependent extracel-
lular vesicle (EV) release is downregulated. This may be a
protective process to limit the potential prothrombotic con-




from healthy, drug-free volunteers, who had given written,
informed consent in accordance with the Declaration of Hel-
sinki. Use of human blood for these experiments was approved
by theHumanBiologyResearchEthics Committee, Universityof
Cambridge. Acid citrate dextrose (85 mM trisodium citrate,
71 mM citric acid, 111 mM D-glucose) was added (1:7 v/v)
and platelet-rich plasma (PRP) separated by centrifugation
(200  g, 10 minutes). Prostaglandin E1 (100 nM) and apyrase
(Grade VII; 0.02 U/mL) were added to PRP to prevent platelet
activation during preparation. Where required, platelets were
incubated with either Fluo-4-acetoxymethyl (AM) or calcein-
AM (both 1 µM; 10 minutes). Platelets were pelleted from PRP
by centrifugation (600  g, 10 minutes) and resuspended in
HEPES-buffered saline (in mM: 10 HEPES, 135 NaCl, 3 KCl, 0.34
NaH2PO4, 1MgCl2.6H2O, pH7.4; supplementedwith0.9 mg/mL
D-glucose) at 5  107 platelets/mL. Platelets were rested (30°C,
30 minutes) prior to treatment with inhibitors or stimulation.
CaCl2 (2 mM) was added immediately prior to simulation.
Flow Cytometry Analysis
Following stimulation, samples were stained with fluorescein
isothiocyanate (FITC)-conjugatedannexinV(AnV) (eBioscience,
ThermoFisher, United Kingdom), to detect exposed PS (FL1),
unless otherwise indicated, and PE-Cy7-conjugated anti-CD41
antibody (eBioscience, ThermoFisher), to distinguish platelet-
derived events. Samples were analyzed using a BD Accuri C6
flow cytometer. PE-Cy7 fluorescence (FL3) was used to trigger
event acquisition. PS-positive platelet-derived EVs were
defined as CD41þ/AnV-positive (AnVþ) events that were
smaller than 1 µm. The 1 µm gate was set in forward scatter
using1 µmsilicabeads.19Tomonitormitochondrialmembrane
potential, washed platelets (5  107/mL) were incubated with
trimetylrhodamine methyl ester (TMRM; 100 µM, 30°C,
30 minutes; ThermoFisher) prior to treatment as indicated in
the main text. TMRM fluorescence was acquired on FL2.
Immunoblotting
Platelet proteins were detected in platelet lysates by sodium
dodecyl sulfate-polyacrylamidegel electrophoresis and immu-
noblotting, essentially as described previously.19 Anti-talin
antibody (clone 8D4; T3287) was from Sigma (Poole, Dorset,
United Kingdom), anti-CD41 antibody (ab134131) was from
Abcam, and anti-caspase3 (9662), anti-gelsolin (8090),
anti-glyceraldehyde 3-phosphate dehydrogenase (2118),
anti-extracellular signal–regulated kinases 1 and 2 (4695),
and anti-COX IV (4850) were from Cell Signaling Technology
(Danvers, Massachusetts, United States), and anti-cytochrome
C (sc-13156)was fromSanta CruzBiotechnology (Dallas, Texas,
United States). The secondary antibodies used were horserad-
ishperoxidase-conjugatedanti-rabbit immunoglobulinG (IgG)
(7074) or anti-mouse IgG (7076; both Cell Signaling
Technology).
Data Presentation and Statistical Analysis
Data are reported as mean  standard error of the mean
from at least 5 independent platelet preparations, com-
pared using one-way or two-way analysis of variance, as
appropriate, in GraphPad Prism v5. Concentration response
curves were fitted using a four-parameter logistical
equation.
Source of Materials
All reagents were obtained from Sigma or ThermoFisher
unless otherwise stated above. ABT-737 was from Selleck
Chemicals.
Results
ABT-737 Triggers Ca2þ-Dependent Apoptosis and
Secondary Necrosis
To investigate platelet apoptosis in vitro, washed human
platelets were treated with ABT-737 (10 µM) for up to
3 hours. ABT-737 triggered cytochrome c release within
10 minutes (►Supplementary Fig. S1A, available in the
online version), which was followed by a slower loss of
mitochondrial membrane potential (►Supplementary
Fig. S1B, available in the online version). PS exposure was
detected by AnV-FITC binding. ABT-737-treated platelets
showed two levels of stimulated AnV binding, AnVmed and
AnVhigh consistent with previous reports20 (►Fig. 1A, B).
Coincident with development of AnVhigh platelets, AnVþ EVs
were detected (►Fig. 1A). The AnVþ EVs detected here are
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likely to be the largest EVs and probably underestimates the
total number of EVs present.19
ABT-737 also triggered an increase in the intracellular Ca2þ
concentration ([Ca2þ]i), whichwas detected using Fluo-4-load-
ed platelets (►Fig. 1C). Since the earliest time analyzed in this
experiment was 10 minutes, the rapid, transient (< 1 minute)
increase in [Ca2þ]i that has beenpreviously reported,17wasnot
detected in this assay. The increase in [Ca2þ]i was largely
Fig. 1 ABT-737 triggers Ca2þ-dependent phosphatidylserine (PS) exposure. (A) Washed human platelets were stimulated with ABT-737 (10 µM, 3 hours),
after which samples were stained with anti-CD41-PerCP-Cy7, and annexin V (AnV)-fluorescein isothiocyanate (FITC) to detect PS exposure. PerCP-Cy7
fluorescencewas used to trigger acquisition of CD41þ events. Thepanels showdensity plots of events from lowdensity (blue in online version; blackdots in
print version) to high density (red in online version; light grey in print version) of forward scatter (FSC-A) and FITC fluorescence. Unstimulated platelets have
high FSC-A and low annexin V-FITC binding (AnVneg). Stimulation with ABT-737 triggers PS exposure at two levels (AnVmed and AnVhigh). The vertical line
separating left and rightwasdefinedby the FSC-Aof1 µmsilicabeads. Thedensityplots are representativeofdata from5differentdonors. Thepercentageof
platelets with indicated AnV binding in the presence or absence of extracellular CaCl2, or in platelets treated with 20 µM BAPTA-AM (n ¼ 5) is shown in
(B) (n ¼ 5; p < 0.01, p < 0.001 forAnVhigh comparedwithplateletswithCaCl2; †††p < 0.001 forAnVmed comparedwithplateletswithCaCl2). (C) Fluo-
4-loaded platelets were stimulated with ABT-737 (or dimethyl sulfoxide [DMSO] as vehicle control) for the indicated times. The Fluo-4 fluorescence of
platelets (CD41 þ , > 1 µm) is shown normalized to thefluorescence of platelets prior to stimulation (p < 0.05, p < 0.01, p < 0.001 comparedwith
DMSO-treated; †p < 0.05,††p < 0.01 fornoCaCl2 comparedwith þ CaCl2 condition). (D)NumberofAnVþextracellular vesicles (EVs) followingstimulation
with ABT-737 for the indicated times in the presence or absence of extracellular CaCl2 or in BAPTA-AM treated platelets (n ¼ 5) (p < 0.01, p < 0.001
compared with DMSO-treated; †††p < 0.001 for ABT-737 þ BAPTA-AM compared with ABT-737 þ CaCl2; for clarity, comparison of ABT-737 no CaCl2 with
ABT-737 þ CaCl2 or with DMSO-treated is not shown).
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dependent on the presence of extracellular Ca2þ, indicated that
it is largely due to Ca2þ entry. Ca2þ entrywas required for ABT-
737-triggered PS exposure and release of AnVþ EVs. AnV
binding was significantly inhibited in the absence of extracel-
lular Ca2þ (►Fig. 1B), as previously reported.20 In addition,
release of AnVþ EVs was also abolished (►Fig. 1D). Notably,
CaCl2waspresent in theAnV staining buffer, as it is required for
AnVbinding toPS. Incontrolexperiments,AnVreadilyboundto
heat-killed platelets when Ca2þ was absent during the treat-
ment and only present in the staining buffer (see►Fig. 2A, for
an example).
In contrast, chelation of intracellular Ca2þ by treating
platelets with BAPTA-AM (20 µM) had less effect. The total
percentage of AnVþ platelets was not affected. Instead, the
percentage of AnVhigh platelets was reduced (at 180 minutes,
5.9  0.8% were AnVhigh, comparedwith 44.7  1.1%; n ¼ 5;
p < 0.001) and the percentage of AnVmed platelets corre-
spondingly increased (at 180 minutes, 50.3  2.2% were
AnVmed, compared with 23.6  2.4%; n ¼ 5, p < 0.001), so
that the total percentage of AnVþ platelets was only slightly
reduced (56.2  2.3% in BAPTA-loaded platelets, compared
with 68.3  3.0%; n ¼ 5, p < 0.05). Release of AnVþ EVs was
abolished (►Fig. 1D), suggesting that their release is linked to
the development of AnVhigh platelets, and not AnVmed
platelets.
Furthermore, some platelets lost plasma membrane
integrity, as detected by loss of calcein fluorescence
(►Fig. 2A), indicating that these platelets had progressed
to secondary necrosis. Following 3 hours’ treatment with
ABT-737, 31.1  1.3% (►Fig. 2B; n ¼ 5) of platelets had lost
plasma membrane integrity. In contrast, following 3 hours’
treatment with the solvent, dimethyl sulfoxide (DMSO), only
1.4  0.1% of platelets had lost plasma membrane integrity
(not shown in ►Fig. 2B for clarity). Absence of extracellular
Ca2þ prevented secondary necrosis, with only 1.6  0.2%
(►Fig. 2B; n ¼ 5) of platelets losing plasma membrane
integrity. Similarly, BATPA-loading also prevented secondary
necrosis, with only 6.0  0.4% (►Fig. 2B; n ¼ 5) of platelets
losing plasma membrane integrity. Together, these data
show that ABT-737 triggers secondary necrosis in a Ca2þ-
dependent manner.
ABT-737-Induced Platelet Apoptosis is Caspase-
Dependent Whereas Secondary Necrosis Requires
Calpain
Cell deathmechanisms often require intracellular proteases.21
ABT-737 triggered cleavage of caspase-3 and its substrate,
gelsolin (►Supplementary Fig. S2, available in the online
version). Platelet AnV binding, AnVþ EV release, and loss of
calcein fluorescence were inhibited by the pan-caspase
Fig. 2 ABT-737 treatment leads to secondary necrosis. (A) Platelets were loaded with calcein, treated as indicated and stained with anti-CD41-
PerCP-Cy7, and annexin V-APC. Density plots are gated on platelets (CD41 þ , > 1 µm) and are representative of 5 independent experiments.
The percentage of calcein negative (-ve) platelets is shown in (B) (n ¼ 5; p < 0.01 for CaCl2 vs. no CaCl2; †††p < 0.001 for CaCl2 vs. BAPTA).
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inhibitor, QVD-Oph (50 µM;►Fig. 3). QVD-Oph did not inhibit
cytochrome c release from mitochondria, consistent with this
beingupstreamofcaspaseactivationduring intrinsic apoptosis
(►Supplementary Fig. S1A, available in theonlineversion) but
did prevent the loss of mitochondrial membrane potential
(►Supplementary Fig. S1B, available in the online version).
In contrast, the Ca2þ-dependent protease, calpain, had a more
restricted role in these responses. Calpeptin (140 µM), a cal-
pain inhibitor, partially inhibited AnVhigh binding, with a
corresponding increase in AnVmed binding (►Fig. 3A). Calpep-
tin did not significantly affect the loss of mitochondrial mem-
brane potential (►Supplementary Fig. S1B, available in the
online version). Although calpain activation is required for
release of AnVþ EVs in response to Ca2þ ionophores or pro-
thrombotic agonists,19,22,23 calpeptin had a statistically signif-
icant, but small, inhibition of AnVþ EVs in response to ABT-737
(►Fig. 3B). Thus, calpain has a relatively restricted role in the
release of these AnVþ EVs.
Interestingly, calpeptin inhibited the loss of calcein fluores-
cence inABT-737-treatedplatelets (►Fig. 3C, D), indicating that
calpain activation in apoptotic platelets leads to loss of plasma
membrane integrity. In addition, the percentage of AnVhigh
Fig. 3 ABT-737-inducedplatelet apoptosis is caspase-dependent whereas secondarynecrosis requires calpain. (A,B) Plateletswere treatedwith thecaspase
inhibitor, Q-VD-Oph (50 µM), the calpain inhibitor, calpeptin (140 µM), or the vehicle (dimethyl sulfoxide [DMSO]) prior to stimulationwith ABT-737 for the
indicated times. The percentage of platelets with the indicated level of annexin V (AnV) binding is shown in (A) (n ¼ 5; p < 0.05, p < 0.01 for AnVhigh
compared with DMSO-treated platelets; ††p < 0.01, †††p < 0.001 for AnVmed compared with DMSO-treated platelets). The number of AnVþ extracellular
vesicles (EVs) detected is shown in (B) (n ¼ 5; p < 0.01, p < 0.001 compared with ABT-737-treated platelets). (C, D) Calcein-loaded platelets were
treated with Q-VD-Oph or calpeptin then with ABT-737. The mean percentage of calcein -ve platelets is shown in (C), and representative density plots are
shown in (D) (n ¼ 5; p < 0.01 compared with ABT-737-treated platelets).
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platelets was partially reduced (29.2  2.1% in calpeptin-
treated platelets, compared with 50.5  2.3% in DMSO-treated
platelets; n ¼ 5; p < 0.01; ►Fig. 3A). Some of these AnVhigh
platelets may in fact be secondary necrotic platelets with a
compromised plasma membrane.
Calpain-Dependent Release of AnVþ EVs is
Downregulated during Apoptosis
It was surprising that calpain is only weakly involved in
ABT-737-triggered release of AnVþ EVs, since calpain is
required for release of AnVþ EVs in response to Ca2þ
ionophores or procoagulant agonists.19,23 We hypothesized
that ABT-737 treatment might somehow reduce the ability
of calpain to promote release of AnVþ EVs. To investigate
this further, platelets were treated with ABT-737 for
3 hours in the absence of extracellular Ca2þ (as very few
AnVþ EVs are released under these conditions). The plate-
lets were then stimulated with the Ca2þ ionophore, A23187
(10 µM), for 10 minutes in the presence of extracellular
Ca2þ, to trigger a large increase in intracellular Ca2þ con-
centration (►Fig. 4A) A Ca2þ ionophore was used rather
than physiological agonists that also trigger AnVþ EV
Fig. 4 Calpain-dependent release of annexin V-positive (AnVþ) extracellular vesicle (EVs) is downregulated during apoptosis. (A) Scheme of the
experiment. Platelets were treated with Q-VD-Oph (or dimethyl sulfoxide [DMSO] as vehicle control; 30 minutes) prior to ABT-737 (10 µM; or
DMSO) in the absence of extracellular CaCl2. After 3 hours of ABT-737, platelets were treated with various concentrations of Ca
2þ ionophore,
A23187, with 2 mM CaCl2, for 10 minutes. Representative density plots are shown in (B). The number of AnV
þ EVs detected is shown in (C), and
total platelet AnV binding (AnVmed þ AnVhigh) is shown in (D) (n ¼ 5; p < 0.01, p < 0.001 compared with DMSO-treated platelets). In (E),
platelets were treated with ABT-737 for 10 or 180 minutes in the same manner as for (A–D). Subsequent A23187 stimulation (10 µM,
10 minutes) led to cleavage of the calpain substrate, talin, which is unaffected by either ABT-737 or Q-VD-Oph. The blot was stripped and
reprobed for CD41, as a loading control, and is representative of 5 independent experiments.
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release (such as thrombin and collagen-related peptide)
since ABT-737 treatment disrupts the responses to these
agonists,6,7 whereas the Ca2þ ionophore can bypass these
disruptions.
As expected, A23187/CaCl2 rapidly triggered release of
AnVþ EVs, whereas ABT-737 triggered very little release of
AnVþ EVs in the absence of extracellular Ca2þ (►Fig. 1D).
However, treatment with ABT-737 inhibited the AnVþ EV
release in response to subsequent stimulation with
A23187/CaCl2 (►Fig. 4B, C). A23187-triggered PS exposure
was unaffected (►Fig. 4D). A23187/CaCl2 was still able to
activate calpain under these conditions, as shown by
cleavage of talin (►Fig. 4E). These data suggest that
Ca2þ/calpain-dependent release of AnVþ EVs are down-
regulated during apoptosis. The importance of this process
is seen when apoptosis was activated but caspases were
inhibited (►Fig. 4B, C). These platelets released more AnVþ
EVs in response to A23187, indicating that ABT-737 makes
platelets more sensitive to A23187 if caspases are not
activated.
Discussion
Apoptosis of platelets in vivo leads to their rapid clearance
from the circulation.3,6 Platelet apoptosis can be activated
in vitro by ABT-737, making this a useful tool to study the
signaling events involved. ABT-737-induced platelet death
has been described as apoptosis since ABT-737 triggers
cytochrome c release and caspase-3 activation. ABT-737-
induced platelet death was not only blocked by caspase
inhibitors6,7 but also absent in Bak/Bax/ mouse plate-
lets,3 further indicating that it is dependent on the intrinsic
apoptosis pathway. However, our data indicate that the
responses to ABT-737 in vitro are not a single event, but a
temporal sequence of stages leading through to secondary
necrosis, each regulated differently by intracellular signal-
ing. These are distinguished by the level of AnV binding,
release of AnVþ EVs, and loss of plasma membrane integ-
rity (►Fig. 5). We propose that this last stage represents
secondary necrosis.
Two levels of AnV binding were detected, AnVmed and
AnVhigh. The latter is similar to the level seen in platelets
stimulated with the Ca2þ ionophore, A23187, or procoagu-
lant combinations of agonists (e.g., thrombin plus collagen-
related peptides).19 van Kruchten et al reported a similar
pattern in platelets from healthy donors.20 (The “M2”
population in their study corresponds to AnVmed here,
and “M3” corresponds to AnVhigh here.) One important
observation from their study was that when platelets
from a patient with Scott syndrome were treated with
ABT-737, most AnVþ platelets were AnVmed, with few
AnVhigh platelets. Similarly, in ABT-737-treated platelets
from Tmem16f/ mice, most AnVþ platelets were AnVmed
rather than AnVhigh.24 This suggests that the higher level of
PS exposure is due to activation of the Ca2þ-dependent
phospholipid scramblase, TMEM16F, which is defective in
Scott syndrome.25 TMEM16F is not responsible for the
lower level of PS exposure (AnVmed). Another scramblase
may be involved, such as the caspase-activated scramblase,
XKR8,26 although this has yet to be reported in platelets.
TMEM16F may be activated by the slow rise in [Ca2þ]i
detected in Fluo-4-loaded platelets.7 This rise was largely
Fig. 5 ABT-737 triggers apoptosis and secondary necrosis. ABT-737 triggers a sequence of responses in platelets that can be distinguished by
their sensitivity to different inhibitors. Medium phosphatidylserine (PS) exposure (annexin V [AnVmed] binding) is triggered in a caspase-
dependent manner. There is a slow progression to higher PS exposure (AnVhigh binding), which is blocked by chelation of intracellular Ca2þ by
BAPTA. These platelets release AnV-positive (AnVþ) extracellular vesicles (EVs) in a calpain-independent manner. Slowly, platelets begin to lose
plasma membrane integrity, becoming secondary necrotic. This is dependent on calpain. Caspase activation is required for all these responses
and downregulates the rapid release of AnVþ EVs in response to A23187 and an acute increase in intracellular Ca2þ. Thus, platelet apoptosis
slowly progresses to secondary necrosis if it is not cleared. During the early apoptotic phase, caspases also protect platelets from the effects of
prothrombotic stimuli by downregulating the rapid release of prothrombotic EVs.
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due to Ca2þ entry, as it was substantially reduced in the
absence of extracellular Ca2þ. PS exposure was also depen-
dent on extracellular Ca2þ, as absence of extracellular Ca2þ
reduced the percentage of AnVhigh and AnVmed platelets.
Interestingly, chelation of intracellular Ca2þ with BAPTA
has less effect. AnVhigh binding was inhibited, but AnVmed
binding was slightly enhanced. A similar result is seen in van
Kruchten et al.20 This suggests that intracellular BAPTA
inhibits the large [Ca2þ]i signals required to activate
TMEM16F but has little effect on the TMEM16F-independent
scrambling pathway. In contrast, there is an additional role
for extracellular Ca2þ. This may be to support Ca2þ entry, or
there may be an extracellular site of action.27 Whatever the
precise roles of Ca2þ in these two pathways of PS exposure,
“apoptosis” in response to ABT-737 has distinct stages regu-
lated in different manners.
After prolonged treatment with ABT-737, some platelets
lost plasma membrane integrity, suggesting that these
platelets have entered secondary necrosis. The progression
to secondary necrosis required caspase activation and ex-
tracellular and intracellular Ca2þ. It also required calpain, a
Ca2þ-dependent protease (►Fig. 5). Calpain is a major
effector of necrotic cell death, and its substrates include
cytoskeletal proteins, ion transporters, adhesion molecules,
kinases, phosphatases, and phospholipases.28,29 The role of
calpain in secondary necrosis may account for its small
apparent role in PS exposure where the percentage of
AnVhigh platelets was partly reduced (►Fig. 3A). Some of
these AnVhigh platelets may in fact be secondary necrotic
platelets with a compromised plasma membrane. This has
an important consequence for interpreting in vitro studies
with ABT-737, many of which show a similar, partial
inhibitions of the percentage of platelets that bind
AnV.12,14,15 Although these studies are usually interpreted
as showing the role of different signaling pathways in
platelet apoptosis, it is possible that they are instead
showing effects on secondary necrosis.
Surprisingly, calpain has little role in the release of AnVþ
EVs during platelet apoptosis. It is surprising since calpain is
required for AnVþ EV release in response to Ca2þ ionophores
or procoagulant agonists.30 The AnVþ EVs appear to derive
from the AnVhigh platelets, since BAPTA inhibited AnVhigh
binding and AnVþ EV release. AnVhigh platelets have a
similar level of PS exposure to procoagulant platelets and,
as discussed above, are likely to require TMEM16F in the
same way as agonist-induced procoagulant platelets. Thus,
the AnVhigh platelets and the AnVþ EVs generated by ABT-
737 appear the same as those generated by procoagulant
agonists. The difference is that ABT-737 stimulation first
triggers caspase activation (with AnVmed binding), and
AnVhigh binding develops more slowly from these platelets.
Our data show that caspase activation inhibits the ability of
platelets to subsequently release AnVþ EVs in response to
A23187. It appears that caspases downregulate calpain-
dependent AnVþ EV release. This may be important to limit
the procoagulant consequences of platelets undergoing
apoptosis. ABT-737 triggers mitochondrial outer membrane
permeabilization (MOMP) within 10 minutes through Bax/
Bak but independently of subsequent caspase activation
(►Supplementary Fig. S1 [available in the online version]
and Ref.31). During apoptosis, MOMP allows mitochondrial
cytochrome c release and activation of effector caspases.32
MOMP also leads to gradual decline of mitochondrial func-
tion.32–34 This disruption of mitochondrial function may
make platelets more sensitive to procoagulant stimuli, such
as Ca2þ ionophores. This was seen when ABT-737 increased
the release of AnVþ EVs in response to A23187 when
caspases were inhibited. Caspases may therefore limit the
potential consequences of this by inhibiting Ca2þ/calpain-
dependent release of AnVþ EVs.
Together these data suggest that induction of apoptosis
in platelets triggers a temporal sequence of events.
Initially, apoptotic stimuli such as ABT-737 lead to activa-
tion of effector caspases. PS is exposed, which acts as an
“eat-me” signal for clearance of the apoptotic platelet.35 At
the same time, platelets become more sensitive to some
procoagulant stimuli that cause an acute rise in [Ca2þ]i.
However, caspases inhibit calpain-dependent release of
AnVþ EVs, providing a period of reduced capacity to
activate platelets, allowing for their safe clearance from
the circulation.
However, if the platelet is not cleared (as it will not in
vitro owing to lack of scavenger cells), calpain activation
leads to loss of plasma membrane integrity and secondary
necrosis. Although it is unlikely that platelets normally
reach this stage in vivo, rapid induction of apoptosis in
many platelets could temporarily overwhelm the capacity
to clear them. Circulating AnVþ platelets were readily
detectable following ABT-737 administration in mice and
an approximately 90% loss of platelet count.6 This suggests
that if a chemotherapy agent rapidly induced widespread
platelet death, the clearance of these dead cells could be
temporarily overwhelmed. Impaired clearance and accu-
mulation of secondary necrotic cells has been associated
with activation of the adaptive immune system and chronic
inflammation.18 Necrotic cells release intracellular mole-
cules that act as extracellular signal molecules, known as
damage-associated molecular patterns (DAMPs), that acti-
vate innate immune cells via receptors including Toll-like
receptors.36,37 Many DAMPs are now also associated with
thrombosis.38–40 Although secondary necrotic cells may
also release DAMPs, these may have been modified by prior
activation of caspases during apoptosis, leading to a differ-
ent pattern of inflammatory and immunogenic events.41
Impaired clearance of apoptotic cells is also associated with
the development of autoantibodies against intracellular
antigens and chronic inflammation.18,42 Although the con-
sequences of platelet secondary necrosis are yet to be
determined, a large number of circulating secondary ne-
crotic cells would have the potential to promote acute and
chronic inflammation.
In summary, apoptotic platelets progress to secondary
necrosis unless they are cleared. Some of the signaling
events described in vitro may reflect platelet secondary
necrosis, rather than early apoptosis. AnVþ EV release is
downregulated during apoptosis in a caspase-dependent
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manner, which may limit the prothrombotic consequences
of cell death.
What is known about this topic?
• Platelet lifespan is controlled by intrinsic apoptosis.
• BH3 mimetics, such as ABT-737, can trigger platelet
apoptosis in vivo and in vitro.
• ABT-737 is commonly used to study the signaling
involved in platelet apoptosis in vitro.
What does this paper add?
• Apoptotic platelets progress to secondary necrosis in
vitro as they are not cleared.
• The intracellular signaling involved in the stages of apo-
ptosis and secondary necrosis is different, which affects
the interpretation of platelet apoptosis studies in vitro.
• During platelet apoptosis, caspases downregulate the
release of procoagulant extracellular vesicles from
platelets in response to stimulation.
Note
The data are available from the corresponding author on
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